| 000 | 01749 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518002246.0 | ||
| 264 | 0 | _c20190510 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1432-1106 | ||
| 024 | 7 |
_a10.1007/s00221-018-5390-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFrouni, Imane | |
| 245 | 0 | 0 |
_aEffect of the selective 5-HT _h[electronic resource] |
| 260 |
_bExperimental brain research _cJan 2019 |
||
| 300 |
_a29-36 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenergic Agents _xtoxicity |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBiogenic Monoamines _xmetabolism |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFunctional Laterality _xdrug effects |
| 650 | 0 | 4 |
_aIndoles _xblood |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
| 650 | 0 | 4 |
_aPiperazines _xblood |
| 650 | 0 | 4 |
_aPsychomotor Performance _xdrug effects |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aSerotonin 5-HT2 Receptor Antagonists _xblood |
| 700 | 1 | _aKwan, Cynthia | |
| 700 | 1 | _aBédard, Dominique | |
| 700 | 1 | _aBelliveau, Sébastien | |
| 700 | 1 | _aBourgeois-Cayer, Élodie | |
| 700 | 1 | _aGaudette, Fleur | |
| 700 | 1 | _aBeaudry, Francis | |
| 700 | 1 | _aHamadjida, Adjia | |
| 700 | 1 | _aHuot, Philippe | |
| 773 | 0 |
_tExperimental brain research _gvol. 237 _gno. 1 _gp. 29-36 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00221-018-5390-4 _zAvailable from publisher's website |
| 999 |
_c28916721 _d28916721 |
||